JAK2 rs77375493: Understanding the V617F Variant
The rs77375493 variant in the JAK2 gene, commonly known as V617F, is a well-established driver mutation frequently identified in myeloproliferative neoplasms. This variant causes the JAK2 protein to remain constantly active, which influences the production of blood cells in the bone marrow.
What each genotype means
Typical JAK2 profile
This genotype represents the wild-type or normal sequence for this position in the JAK2 gene. It is the most common state found in the general population and is not associated with the gain-of-function mutations linked to myeloproliferative neoplasms.
This is the predominant genotype found in the vast majority of the human population.
JAK2 V617F variant present
This genotype indicates the presence of the V617F mutation, a well-established gain-of-function change in the JAK2 gene. This mutation is typically acquired somatically rather than inherited, and it is strongly associated with myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. If this result was obtained from clinical testing, please consult with a hematologist or medical professional to discuss its significance in the context of your health.
This variant is extremely rare in the general population and is primarily identified in clinical settings among patients with specific blood disorders.
JAK2 V617F homozygous variant
This genotype indicates a homozygous state for the V617F mutation, where both copies of the gene carry the change. This state is often associated with more advanced disease progression in individuals already diagnosed with a myeloproliferative neoplasm. Please discuss these findings with your clinician to understand the clinical implications for your specific health situation.
This genotype is exceptionally rare and is almost exclusively observed in the context of clinical disease progression.
What is the rs77375493 Variant?
The rs77375493 variant, widely recognized in scientific literature as the V617F mutation, is a specific change in the DNA sequence of the JAK2 gene. Located on chromosome 9, this variant involves a single nucleotide substitution that results in the replacement of the amino acid valine with phenylalanine at position 617 of the JAK2 protein. Unlike many inherited genetic variants that are passed down from parents, this specific mutation is typically acquired during a person's lifetime. This means it usually arises in a single hematopoietic stem cell within the bone marrow rather than being present in every cell of the body from birth. Because it is a somatic mutation, it is not typically found in germline testing unless specifically investigated in the context of rare familial predisposition studies.
The Role of the JAK2 Gene
The JAK2 gene provides the instructions for creating the Janus kinase 2 protein, which is a member of the tyrosine kinase family. This protein plays a critical role in the JAK/STAT signaling pathway, a communication system that transmits chemical signals from the surface of a cell to its nucleus. These signals are essential for regulating the growth, division, and survival of cells. In the context of the bone marrow, the JAK2 protein is particularly important for the development of hematopoietic stem cells into mature red blood cells, white blood cells, and platelets. When the JAK2 protein functions normally, it is activated only when necessary to support healthy blood cell production. However, the V617F mutation causes the protein to become constitutively active, meaning it is 'always on,' which can lead to the uncontrolled proliferation of blood cells.
Research and Clinical Associations
Research has strongly associated the JAK2 V617F mutation with a group of blood disorders known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). These conditions include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Studies have shown that this mutation is present in a high percentage of patients diagnosed with these conditions, particularly in those with polycythemia vera, where it is found in the vast majority of cases. Because this mutation drives the overproduction of abnormal blood cells, it is considered a primary driver of the disease process. While the presence of this variant is a significant clinical marker, it is important to note that the severity and specific type of MPN can vary between individuals. Scientists continue to study how this mutation interacts with other genetic factors to influence the clinical progression of these blood disorders.
Population Frequency and Prevalence
The frequency of the rs77375493 variant is highly variable because it is primarily an acquired somatic mutation rather than a common inherited polymorphism. In the general population, the variant is extremely rare or absent in healthy individuals. Its prevalence is significantly higher only within specific clinical populations diagnosed with myeloproliferative neoplasms. Because it is not a standard inherited trait, it does not follow typical population frequency patterns seen in common genetic variants. Most population databases report a very low or zero frequency for this variant in the general, healthy population. If you have concerns about your blood counts or symptoms related to these conditions, it is essential to consult with a hematologist or a medical professional who can order appropriate diagnostic testing and interpret the results in the context of your overall health.
Managing Genetic Information
Understanding your genetic information is a powerful tool, but it must be handled with care. The presence of the JAK2 V617F variant is a clinical finding that requires professional medical interpretation. It is not a diagnosis on its own, and its presence does not automatically mean an individual will develop a specific disease. If you have received results indicating the presence of this variant, you should discuss the findings with your clinician or a genetic counselor. They can help you understand what this means for your health, whether further monitoring is necessary, and how to manage any associated risks. Never attempt to diagnose yourself or make changes to your health regimen based on genetic data alone. Always rely on the guidance of qualified healthcare providers who can integrate your genetic results with your clinical history and physical examinations.
How common is this variant?
The rs77375493 variant is an acquired somatic mutation that is extremely rare in the general population and is primarily found in individuals diagnosed with myeloproliferative neoplasms.
Frequently asked questions
Is the JAK2 V617F mutation inherited from parents?
No, the JAK2 V617F mutation is typically an acquired somatic mutation. This means it occurs in a person's cells during their lifetime and is not passed down from parents to children.
Does having the JAK2 V617F mutation mean I have cancer?
The presence of this mutation is a hallmark of certain myeloproliferative neoplasms, which are blood disorders. However, it is a clinical finding that must be evaluated by a doctor in the context of your blood counts and symptoms to determine a diagnosis.
Can I get tested for the JAK2 V617F mutation?
Yes, testing for this mutation is available through clinical laboratories, usually ordered by a hematologist. It is typically performed when a doctor suspects a myeloproliferative neoplasm based on abnormal blood test results.
What should I do if I find out I have this variant?
If you have been informed that you carry this variant, you should schedule an appointment with a hematologist. They will review your medical history and blood work to determine if any follow-up or treatment is necessary.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs77375493?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in JAK2
This variant is part of the JAK2 46/1 haplotype, which predisposes individuals to V617F-positive myeloproliferative neoplasms.
This variant is associated with a 2-4 fold increased risk of developing V617F-associated myeloproliferative neoplasms (MPNs).